


diABZI STING agonist-1 trihydrochloride

Cat. No.:	HY-112921B
CAS No.:	2138299-34-8
Molecular Formula:	C ₄₂ H ₅₄ Cl ₃ N ₁₃ O ₇
Molecular Weight:	959.32
Target:	STING
Pathway:	Immunology/Inflammation
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 90 mg/mL (93.82 mM; Need ultrasonic)
H₂O : 25 mg/mL (26.06 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		1.0424 mL	5.2120 mL	10.4241 mL
	5 mM		0.2085 mL	1.0424 mL	2.0848 mL
	10 mM		0.1042 mL	0.5212 mL	1.0424 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 33.33 mg/mL (34.74 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (2.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (2.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.17 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

diABZI STING agonist-1 (trihydrochloride) is a selective stimulator of interferon genes (STING) receptor agonist, with EC₅₀s of 130, 186 nM for human and mouse, respectively.

IC₅₀ & Target

STING^[1].

In Vitro

diABZI STING agonist-1 is a selective stimulator of interferon genes (STING) receptor agonist, with EC₅₀s of 130, 186 nM for

human and mouse, respectively. At a concentration of 1 μ M, diABZI STING agonist-1 (compound 3) demonstrates high selectivity against more than 350 kinases tested^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

diABZI STING agonist-1 trihydrochloride (subcutaneous injection; 2.5 mg/kg) induces STING-dependent activation of type-I interferon and pro-inflammatory cytokines in vivo^[1].

diABZI STING agonist-1 trihydrochloride (intravenous injection; 3 mg/kg) exhibits systemic exposure with a half-life of 1.4 h and achieves systemic concentrations greater than the half-maximal effective concentration (EC₅₀) for mouse STING (200 ng/ml)^[1].

diABZI STING agonist-1 trihydrochloride (intravenous injection; 1.5 mg/kg; days 1, 4 and 8; 43 days) results in significant tumour growth inhibition and significantly improves survival (P < 0.001) with 8 out of 10 mice remaining tumor free at the end of the study on day 43^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild and Sting ^{-/-} C57Blk6 mice ^[1]
Dosage:	2.5 mg/kg
Administration:	Subcutaneous injection; 2.5 mg/kg
Result:	Activated secretion of IFN β , IL-6, TNF, and CXCL1 in wild-type but not Sting ^{-/-} mice.

Animal Model:	Syngeneic mouse model of colorectal tumours (CT-26) in BALB/c mice ^[1]
Dosage:	3 mg/kg
Administration:	Intravenous injection; 3 mg/kg
Result:	Exhibited a half-life of 1.4 hours and achieved systemic concentrations greater than EC ₅₀ for mouse STING (200 ng/ml).

Animal Model:	Syngeneic mouse model of colorectal tumours (CT-26) in BALB/c mice ^[1]
Dosage:	1.5 mg/kg
Administration:	Intravenous injection; 1.5 mg/kg; 43 days
Result:	Resulted in significant tumour growth inhibition and improved survival.

CUSTOMER VALIDATION

- Nat Nanotechnol. 2021 Sep 30.
- Protein Cell. 2021 Oct 22;1-21.
- Mol Cell. 2023 Apr 14;S1097-2765(23)00243-5.
- Cell Death Differ. 2023 Nov 25.
- Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018 Nov 7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA